ArticleNPJ precision oncology2025
Gαi3: a crucial biomarker and therapeutic target in bladder cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer.Journal of cellular and molecular medicine · 2026Article
- Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigates the role of Gαi3 in bladder cancer, focusing on its expression, functions, and mechanisms. Bioinformatics reveal that Gαi3 is overexpressed in bladder cancer, linked to poorer survival and higher tumor grades. Single-cell sequencing data confirm Gαi3 overexpression in bladder cancer epithelial cells. Additionally, Gαi3 is upregulated in tissues from locally treated patients and various bladder cancer cells. Silencing Gαi3 with targeted shRNA inhibited cell proliferation, migration, and invasion, activating caspase-mediated apoptosis. CRISPR/Cas9-mediated knockout of Gαi3 also exhibited significant anti-cancer effects, while overexpression enhanced cell proliferation and mobility. Gαi3 activates the Akt-mTOR pathway; silencing or knockout reduced phosphorylation of Akt and S6K, while overexpression increased it. The anti-cancer effects of Gαi3 shRNA were lessened by reactivating Akt-mTOR with a constitutively active Akt1 mutant. We observed a stronger binding affinity between the Gαi3 promoter and the transcription factor GATA4 in bladder cancer tissues. GATA4 silencing lowered Gαi3 expression, while GATA4 overexpression increased it. In vivo, Gαi3 silencing significantly hindered the growth of bladder cancer xenografts in nude mice, along with inactivation of the Akt-mTOR pathway and increased apoptosis. These results highlight Gαi3's functional role in bladder cancer progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.